Objectives: People experiencing trafficking often seek health care but are not identified. Although the Centers for Disease Control and Prevention added new (ICD-10-CM) codes specific to human trafficking (hereinafter, HT ICD-10-CM codes) that could systematize the identification and documentation of human trafficking in US health care settings, the extent of their use is unknown. The objectives of this study were to investigate (1) the frequency of HT ICD-10-CM code use in US health care organizations (HCOs) and (2) demographic data associated with HT ICD-10-CM codes using a large clinical database.
Methods: This retrospective study used deidentified data collected from October 1, 2018, through March 30, 2021, from a clinical database (N = 69 740 144 patients) network (TriNetX) of 48 collaborating US HCOs. Data included number of patients with ≥1 HT ICD-10-CM code, diagnoses, and demographic characteristics (age, sex, race, ethnicity, and region).
Results: HT ICD-10-CM codes were associated with 298 patients in US HCOs, most of whom were young (mean [SD] age, 26 [16] y), White (53.0%; n = 158), and female (87.9%; n = 262). Thirty-seven of 48 (77.1%) participating HCOs used ≥1 HT ICD-10-CM code. The most frequently used HT ICD-10-CM codes were "forced sexual exploitation, suspected" (32.2%; n = 96) and "personal history of forced labor or sexual exploitation" (27.1%; n = 81). Labor trafficking codes were noted in approximately 3.7% of cases.
Conclusions: HT ICD-10-CM codes are being used by health care professionals, as confirmed by large databases. Further research is needed to understand variation in code use and risk factors associated with human trafficking.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257483 | PMC |
http://dx.doi.org/10.1177/00333549221095631 | DOI Listing |
J Affect Disord
January 2025
School of Population Health, Curtin University, Perth, WA, Australia; enAble Institute, Curtin University, Perth, Western Australia, Australia.
Background: This study aims to examine the relationship between maternal antenatal and postnatal depressive disorders and the risk of disruptive behavioural disorders (DBDs) in offspring, including conduct disorder (CD) and oppositional defiant disorder (ODD), to enhance understanding and address gaps in the literature.
Methods: We utilised a large administrative health dataset from New South Wales (NSW), Australia. Maternal perinatal depressive disorders and offspring DBDs were identified using International Classification of Diseases (ICD-10) codes.
Child Abuse Negl
January 2025
Division of Epidemiology, School of Public Health, University of California, 2121 Berkeley Way West, Berkeley, CA 94720, USA; Division of Biostatistics, School of Public Health, University of California, 2121 Berkeley Way West, Berkeley, CA 94720, USA.
Background: The number of U.S. deaths due to child maltreatment (abuse and neglect) has been increasing over several years.
View Article and Find Full Text PDFClin Chem
January 2025
Division of Maternal-Fetal-Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Background: Genetic screening has advanced from prenatal cell-free DNA (cfDNA) screening for aneuploidies (cfDNA-ANP) to single-gene disorders (cfDNA-SGD). Clinical validation studies have been promising in pregnancies with anomalies but are limited in the general population.
Methods: Chart review and laboratory data identified pregnancies with cfDNA-SGD screening for 25 autosomal dominant conditions at our academic center.
Acta Derm Venereol
January 2025
Technical University of Munich, TUM School of Medicine and Health, Department of Dermatology and Allergy, Munich, Germany; Division of Dermatology and Venereology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
The comorbidity cycle between psoriasis and addictions remains unclear. The study aimed to investigate the cumulative incidence of addictions in psoriasis patients and controls in the Stockholm Psoriasis Cohort (SPC). The SPC is an observational cohort study that enrolled psoriasis patients between 2001 and 2005 and matched controls using the Swedish Total Population Register.
View Article and Find Full Text PDFDrugs Aging
January 2025
Pharmacy Outcomes Research Group, Kaiser Permanente, 12254 Bellflower Blvd, Downey, CA, 90242, USA.
Background And Objective: Quetiapine is a Food and Drug Administration (FDA) approved second-generation antipsychotic. It is also commonly used at low dose for its sedative properties to treat insomnia in the older population. Quetiapine at standard doses has been associated with increased risk of cerebrovascular events, cognitive decline, and mortality in patients with dementia, especially within older adults.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!